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We thank Professor Heitjan for his concise overview of our paper1 and stimulating commentary.2 We agree 
that none of the methods designed to address this problem is completely satisfactory. The approach we 
advocate recognises that, when presented with findings from trials that have missing data, experts readily 
come to a view about the relative benefits of the intervention. In doing so they incorporate (often 
implicitly) an opinion about the missing data, but these opinions are not made transparent, nor are they 
subject to scrutiny. Therefore, we believe it is useful to capture and quantify these views, so all those with 
an interest in the research can review and critique them. By making the use of expert opinion transparent, 
our approach helps facilitate a more informed interpretation of a study with missing data. We now turn to 
the specific points raised, before proposing a route forward. 
First, do the experts understand the questions? This is clearly crucial. We therefore went to considerable 
lengths to pilot and refine our approach, in order to make it accessible and accurate. To engage the experts, 
we asked them to consider typical patients who did and did not have missing data. We sought to elicit 
information about differences between those with and without missing data in the mean outcome. To 
provide insights into why the experts gave the responses that they did, we also collected qualitative 
information, which suggested that they had indeed understood the questions. However, it is possible that 
not all experts fully understood what we were asking. It is also unclear whether all those using findings 
from an empirical study with missing data fully understand the assumptions behind the analyses 
undertaken. We do not accept that it follows that because experts’ views differ markedly they did not 
understand the question. More likely, it represents markedly different, but quite strong, opinions. 
Second, why do doctors and nurses give different answers? Doctors and nurses have different perspectives. 
Thus, the finding that they give somewhat different answers could reflect alternative viewpoints and 
training. The suggestion of a follow-up study to explore this issue further is a good one; in the meantime, 
we note that doctors involved in surgery are possibly more prone to optimism bias for the less invasive 
endovascular strategy versus open repair, whereas nurses, who are more closely involved helping patients 
recover post-surgery, are not. 
Third, how much should we credit individual priors? Our anecdotal experience is that ‘true believers’ tend 
to be forthright and assertive. In our approach, their view (and that of the ‘sceptic’) is diluted, as it is 
combined with ‘mainstream’ views prior to analysis. Moreover, by analysing the data with, and without, 
the ‘true believers’ views, we can quantify their impact. An alternative approach would be to perform a 
Delphi elicitation process, where outlying views would be challenged and resolved. However, such 
processes are unduly burdensome and costly in most settings, and might not reflect the full range of views 
seen in practice – hence our approach. 
Fourth, was the sample of experts adequate? We agree the study would have been improved by collecting 
requisite background information that would have enabled us to fully assess the representativeness of our 
experts. Our defence is that this is an initial attempt at developing this approach. We did partly address this 
concern in presenting results according to a predefined subgroup (doctor versus nurse), and also we had 
good site coverage with responding experts from 18 out of the 30 IMPROVE trial sites.  
Fifth, were the priors correct? The proposal for an empirical study to calibrate the views of experts to some 
observations on the patients with missing data, while challenging, is an excellent idea. 
We believe this field could be moved forward by: A study of the kind proposed above; greater use of the 
approach, which will raise awareness of the issues and how to address them, and stimulate; further 
research on the best way to elicit information. 
In summary, while we support Prof Heitjan’s proposal that experts should be encouraged to suggest 
alternative data that can shed light on these questions, we believe this is only a part of the solution. The 
views of experts are used to make decisions at all levels by individual patients and clinicians, through to 
regulatory, policy-making and grant-funding committees. Formalising such views, combining them 
consistently with the data, and making the process transparent is surely an advance. This approach of 
making the use of expert views transparent, goes way beyond missing data, and to the core issue of how 
evidence can best be used to inform decisions.3  
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